What happens to patients who were in clinical trials for Spinraza?
Patients who participated in either NURTURE or EMBRACE will continue in the trial and receive Spinraza. SMA patients on other trials will be transferred to SHINE and receive Spinraza with continued monitoring.
What will happen to the expanded access program?
Now that Spinraza has been approved by the FDA, the expanded access program will be closed to new enrollments. Families currently enrolled in the EPA should contact Biogen (1-844-477-4672) for more information.